Processa (PCSA) CDO buys 1,799 company shares in open market

Rhea-AI Filing Summary

Processa Pharmaceuticals, Inc. Chief Development Officer Sian Bigora reported an open-market purchase of 1,799 shares of common stock at $2.97 per share on April 15, 2026. Following this trade, Bigora directly holds 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC.

Insights

Insider trading analyst

Processa’s CDO made a modest open-market share purchase, signaling incremental alignment but limited size.

Chief Development Officer Sian Bigora bought 1,799 shares of Processa Pharmaceuticals common stock in an open-market transaction at $2.97 per share. This is a discretionary purchase, not part of a derivative exercise or tax withholding.

After the transaction, Bigora directly owns 5,510 common shares and has indirect ownership of 267 shares through CorLyst, LLC. The filing shows a net-buy pattern but the absolute share count is relatively small, suggesting routine portfolio alignment rather than a thesis-changing move.

Insider Trade Summary

Net Buyer: 1,799 shares ($5,343)

Net Buy 2 txns

Insider Bigora Sian

Role Chief Development Officer

Bought 1,799 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,799	$2.97	$5K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 5,510 shares (Direct); Common Stock — 267 shares (Indirect, By CorLyst, LLC)

Footnotes (1)

Key Figures

Shares purchased: 1,799 shares Purchase price: $2.97 per share Direct holdings after transaction: 5,510 shares +2 more

5 metrics

Shares purchased 1,799 shares Open-market purchase on April 15, 2026

Purchase price $2.97 per share Open-market buy of common stock

Direct holdings after transaction 5,510 shares Common stock directly owned by CDO after trade

Indirect holdings after transaction 267 shares Common stock held indirectly via CorLyst, LLC

Net buy-sell shares 1,799 shares transactionSummary net-buy for this Form 4

Key Terms

open-market purchase, indirect ownership, Form 4, common stock, +1 more

5 terms

open-market purchase financial

"reported an open-market purchase of 1,799 shares of common stock"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"has indirect ownership of 267 shares through CorLyst, LLC"

Form 4 regulatory

"The PCSA Form 4 does not list any derivative transactions"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

common stock financial

"purchase of 1,799 shares of common stock at $2.97 per share"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

derivativeSummary financial

"no remaining derivatives reported in the accompanying derivativeSummary"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bigora Sian

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		P		1,799	A	$2.97	5,510	D
Common Stock								267	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sian Bigora by John J. Wolfel, as Attorney-in-Fact	04/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)